X
[{"orgOrder":0,"company":"Nippon Kayaku","sponsor":"Solasia Pharma KK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Solasia and Nippon Kayaku Announce License Agreement in Japan for New Drug Candidate DARINAPARSIN (SP-02)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Nippon Kayaku","sponsor":"Solasia Pharma KK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Solasia Announces Launch of Darvias\u00ae in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase IV"},{"orgOrder":0,"company":"Nippon Kayaku","sponsor":"AnHeart Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$40.0 million","newsHeadline":"AnHeart Therapeutics Announces Exclusive License Agreement with Nippon Kayaku for Taletrectinib in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III"}]
Find Clinical Drug Pipeline Developments & Deals by Nippon Kayaku
Filters
Companies By Therapeutic Area
Details:
Under the terms of the agreement, Nippon Kayaku will be responsible for regulatory approvals and commercialization of AB-106 (taletrectinib) for ROS1-positive NSCLC in Japan, and will have rights to further develop taletrectinib for new indications in the region.
Lead Product(s):
Taletrectinib
Therapeutic Area: Oncology
Product Name: AB-106
Highest Development Status: Phase II/ Phase III
Product Type: Small molecule
Recipient:
AnHeart Therapeutics
Deal Size: Undisclosed
Upfront Cash: $40.0 million
Deal Type: Licensing Agreement
October 30, 2023
Details:
DARVIAS® (darinaparsin), an organoarsenic compound with anticancer activity, is a novel mitochondrial-targeted agent being developed for the treatment of various hematologic and solid tumors.
Lead Product(s):
Darinaparsin
Therapeutic Area: Oncology
Product Name: Darvias
Highest Development Status: Phase IV
Product Type: Small molecule
Recipient:
Solasia Pharma KK
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
August 22, 2022
Details:
Under the license agreement, Solasia and Nippon Kayaku will make further efforts to provide a new treatment option to patient suffering from PTCL and for marketing rights to darinaparsin.
Lead Product(s):
Darinaparsin
Therapeutic Area: Oncology
Product Name: SP-02
Highest Development Status: Phase II/ Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Solasia Pharma KK
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Licensing Agreement
October 26, 2021